e-Therapeutics - Capital Network: Undervalued Stock with a Unique Approach to Drug Discovery
1.e-Therapeutics (LON:ETX) focuses on the discovery of new drugs in a more efficient and effective way and aims to be a valued partner to address the productivity challenge that the pharma industry faces.
2.e-Therapeutics (LON:ETX) has developed a novel and unique in-silico approach to drug discovery: starting from the analysis of complex interactions between proteins in biological systems (networks), they apply advanced computational techniques to identify new drug candidates.
3.This approach was labeled Network-driven Drug Discovery (NDD) and has been validated across several therapeutic areas (cancer, central nervous system, auto-immunity, infectious diseases) and molecular pathways.
4.e-Therapeutics (LON:ETX) discovery platform has generated three drug candidates for multiple cancer indications which are ready to be out-licensed to pharma partners for their further development.
5.We estimate e-Therapeutics intrinsic value to be roughly 3x higher than current market capitalisation. The latter doesn't reflect the commercial potential of e-Therapeutics' most advanced drug candidates and of the platform itself
- e-Therapeutics ability to finalise a co-development or licensing agreement in the near term will represent a key inflection point for its stock re-rating.
E-Therapeutics is a drug discovery company with a proprietary in silico discovery platform based on the application of network science to the modelling and analysis of cellular processes and utilizing public and proprietary chemical biology and multi-omics data. The therapeutic focus of Co.'s discovery activity is in areas of disease with unmet medical need, including immuno-oncology.
Capital Network is the foremost authority on utilising digitisation to allow companies to achieve their corporate goals, whether those goals pertain to raising capital, increasing investor awareness, boosting liquidity or allowing the business to flourish. We are proud to deliver bespoke, industry-leading services to a broad range of capital market clients. To deliver on our range of digitised services clients are assigned tier-1 analysts who have extensive sector knowledge, numerous accreditations and a track record of delivering success.
The investor community is evolving and we allow investment banks, fund managers, hedge funds, wealth managers, trusts, family offices and private investors the capacity to access new investment ideas as well delivering further insight into their current portfolio. In addition to driving value for our diverse client base, we empower investors with our digital solutions.
Our approach to serving clients takes a traditional method of doing first-class business in a first-class way, in conjunction with implementing the most technologically advanced services for them. We strive to build trusted, long-term relationships built on diligence and foresight, and identifying ways to help clients achieve their most important business objectives.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.